Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies

In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. The benefit was consistent across subgroups, and this regimen is now recommended after chemotherapy for germline BRCA1/2 mutation (gBRCA1/2m) carriers with high-risk, HER2-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Morganti, Stefania, Bychkovsky, Brittany L, Poorvu, Philip D, Garrido-Castro, Ana C, Weiss, Anna, Block, Caroline C, Partridge, Ann H, Curigliano, Giuseppe, Tung, Nadine M, Lin, Nancy U, Garber, Judy E, Tolaney, Sara M, Lynce, Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322138/
https://www.ncbi.nlm.nih.gov/pubmed/37210568
http://dx.doi.org/10.1093/oncolo/oyad123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322138/
https://www.ncbi.nlm.nih.gov/pubmed/37210568
http://dx.doi.org/10.1093/oncolo/oyad123

Ejemplares similares